Abstract
Plants are an important source of chemically diverse natural products that target microtubules, one of the most successful targets in cancer therapy. Colchicine, paclitaxel, and vinca alkaloids are the earliest plant-derived microtubule-targeting agents (MTAs), and paclitaxel and vinca alkaloids are currently important drugs used in the treatment of cancer. Several additional plant-derived compounds that act on microtubules with improved anticancer activity are at varying stages of development. Here, we move beyond the well-discussed paclitaxel and vinca alkaloids to present other promising plant-derived MTAs with potential for development as anticancer agents. Various biological and biochemical aspects are discussed. We hope that the review will provide guidance for further exploration and identification of more effective, novel MTAs derived from plant sources.
Highlights
Microtubules are the major components of the eukaryotic cytoskeleton
Doxorubicin-resistant mouse tumor models [27,34,50]. This improved efficacy of taccalonolides may be explained by its high degree of cellular retention compared to paclitaxel that could be potentially stemmed from their covalent interaction with tubulin [51]
The binding pocket contained H30 -helix, T4 and T5 loops, and the H110 helix [41], demonstrating that curcumin occupies a unique site that partly overlap with the colchicine-site on tubulin
Summary
Microtubules are the major components of the eukaryotic cytoskeleton They are composed of α- and β-tubulin heterodimers that interconvert between phases of rapid growth (polymerization) and shrinkage (depolymerization) [1]. The in paclitaxel and vinca important for identifying novel, more effective antimicrotubule agents. 1) that exhibited bioactivity to cytotoxic activity against cancer culture and/or in xenografts here onwards) superior(termed to paclitaxel and vinca alkaloids, or (2) cells that in culture and/or xenografts here onwards) superior to paclitaxel and vinca alkaloids, or 2) that underwent clinicalintrials are discussed.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
